INJECTABLE COMPOSITIONS FOR THE CONTROLLED DELIVERY OF PHARMACOLOGICALLY ACTIVE COMPOUND

WIPO Patent Application WO2003034988

A3

The present invention provides compositions and methods for extending the release times and lowering the toxicity of pharmacologically active compounds. The compounds comprise a salt of the pharmacologically active compound with a lipophilic counterion and a pharmaceutically acceptable water soluble solvent combined together to form an injectable composition. The lipophilic counterion may be a saturated or unsaturated C8-C22 fatty acid, and preferably may be a saturated or unsaturated C10-C18 fatty acid. When injected into a mammal, at least a portion of the composition precipitates and releases the active compound over time. Thus, the composition forms a slowly releasing drug depot of the active compound in the mammal. Therefore, the present invention enables one to provide a controlled dose administration of the active compound for a periods of up to 15 days or even longer. Many compounds can be administered according to the present invention including, but not limited to, tilmicosin, oxytetracycline, metoprolol, fluoxetine, roxithromycin, and turbinafine.

MURTHY YERRAMILLI V S N (US)
SUVA ROBERT (US)

PCT/US2002/033300

July 31, 2003

October 18, 2002

Click for automatic bibliography generation  

IDEXX LAB INC (US)
MURTHY YERRAMILLI V S N (US)
SUVA ROBERT (US)

A61K9/10; A61K31/137; A61K31/138; A61K9/00; A61K31/165; A61K31/18; A61K31/245; A61K31/4704; A61K31/496; A61K31/505; A61K31/65; A61K31/7036; A61K31/7048; A61K47/10; A61K47/12; A61K47/14; A61K47/20; A61K47/22; A61K47/32; A61K47/34; A61P23/02; A61P31/04; A61K47/26; (IPC1-7): A61K9/00; A61K31/65; A01N37/18

US6403057B1

2002-06-11

See also references of EP 1446103A4

View/Download PDF      PDF Help

Previous Patent: ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF

Next Patent: $g(a)-HYDROXYARYLBUTANAMINE INHIBITORS OF ASPARTYL PROTEASE